JP2010532352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532352A5 JP2010532352A5 JP2010514802A JP2010514802A JP2010532352A5 JP 2010532352 A5 JP2010532352 A5 JP 2010532352A5 JP 2010514802 A JP2010514802 A JP 2010514802A JP 2010514802 A JP2010514802 A JP 2010514802A JP 2010532352 A5 JP2010532352 A5 JP 2010532352A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- alkoxy
- optionally substituted
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 185
- -1 carboxy, hydroxy Chemical group 0.000 claims description 159
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 158
- 125000003342 alkenyl group Chemical group 0.000 claims description 138
- 125000000304 alkynyl group Chemical group 0.000 claims description 138
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- 125000005843 halogen group Chemical group 0.000 claims description 112
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 111
- 125000003118 aryl group Chemical group 0.000 claims description 98
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 87
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 81
- 125000001589 carboacyl group Chemical group 0.000 claims description 81
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 80
- 229910052717 sulfur Inorganic materials 0.000 claims description 80
- 125000001072 heteroaryl group Chemical group 0.000 claims description 76
- 125000004423 acyloxy group Chemical group 0.000 claims description 69
- 125000004122 cyclic group Chemical group 0.000 claims description 61
- 125000003545 alkoxy group Chemical group 0.000 claims description 59
- 229910052760 oxygen Inorganic materials 0.000 claims description 59
- 125000000623 heterocyclic group Chemical group 0.000 claims description 56
- 125000004432 carbon atom Chemical group C* 0.000 claims description 52
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 229910052801 chlorine Inorganic materials 0.000 claims description 40
- 229910052731 fluorine Inorganic materials 0.000 claims description 40
- 229910052794 bromium Inorganic materials 0.000 claims description 38
- 125000001188 haloalkyl group Chemical group 0.000 claims description 38
- 239000000651 prodrug Substances 0.000 claims description 36
- 229940002612 prodrug Drugs 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 36
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 29
- 229910052740 iodine Inorganic materials 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 22
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 21
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 20
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000003386 piperidinyl group Chemical group 0.000 claims description 18
- 125000004193 piperazinyl group Chemical group 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 125000005110 aryl thio group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims description 13
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 208000005176 Hepatitis C Diseases 0.000 claims description 10
- 102000014150 Interferons Human genes 0.000 claims description 10
- 108010050904 Interferons Proteins 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims description 8
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 125000004104 aryloxy group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 102000012479 Serine Proteases Human genes 0.000 claims description 6
- 108010022999 Serine Proteases Proteins 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 125000000962 organic group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 4
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 4
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical class N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003949 imides Chemical class 0.000 claims description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- CRCTZWNJRMZUIO-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropane Chemical group FC(F)(F)[CH]C(F)(F)F CRCTZWNJRMZUIO-UHFFFAOYSA-N 0.000 claims description 2
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 claims description 2
- 101001023866 Arabidopsis thaliana Mannosyl-oligosaccharide glucosidase GCS1 Proteins 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002349 favourable effect Effects 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229950003954 isatoribine Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 229960000329 ribavirin Drugs 0.000 claims description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims description 2
- 229950006081 taribavirin Drugs 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- 150000001504 aryl thiols Chemical class 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 125000000586 2-(4-morpholinyl)ethoxy group Chemical group [H]C([H])(O*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 0 *C(C1)C1(C(NS(O*)(=O)=O)=O)N(*)C(C(CC(*)C1)N1C(C(*)(*)N(*)*)=*)=* Chemical compound *C(C1)C1(C(NS(O*)(=O)=O)=O)N(*)C(C(CC(*)C1)N1C(C(*)(*)N(*)*)=*)=* 0.000 description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- WMJPXKWIHDLOLK-UHFFFAOYSA-N CCc1nc(cccc2)c2nc1OC Chemical compound CCc1nc(cccc2)c2nc1OC WMJPXKWIHDLOLK-UHFFFAOYSA-N 0.000 description 2
- IVFRKPCKIWPVFX-UHFFFAOYSA-N COc1c(cccc2)c2c(N2CCCCC2)nn1 Chemical compound COc1c(cccc2)c2c(N2CCCCC2)nn1 IVFRKPCKIWPVFX-UHFFFAOYSA-N 0.000 description 2
- BAXABXIZQPAJEF-UHFFFAOYSA-N COc1nc(cccc2)c2nc1 Chemical compound COc1nc(cccc2)c2nc1 BAXABXIZQPAJEF-UHFFFAOYSA-N 0.000 description 2
- NXOFEFJRLUEJSH-UHFFFAOYSA-N COc1nc2ccccc2nc1NCc1ccccc1 Chemical compound COc1nc2ccccc2nc1NCc1ccccc1 NXOFEFJRLUEJSH-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000006433 1-ethyl cyclopropyl group Chemical group [H]C([H])([H])C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- RPFPQLQEDIASGA-UHFFFAOYSA-N CC(C)N(Cc(cc(cc1)F)c1N1)C1=O Chemical compound CC(C)N(Cc(cc(cc1)F)c1N1)C1=O RPFPQLQEDIASGA-UHFFFAOYSA-N 0.000 description 1
- HCIFFIPSGMMRMU-UHFFFAOYSA-N CC(C)N(Cc1c(C2)c(OC)ccc1)C2=O Chemical compound CC(C)N(Cc1c(C2)c(OC)ccc1)C2=O HCIFFIPSGMMRMU-UHFFFAOYSA-N 0.000 description 1
- RZALQYQCABSXLA-UHFFFAOYSA-N CC(C)Nc1n[nH]cc1 Chemical compound CC(C)Nc1n[nH]cc1 RZALQYQCABSXLA-UHFFFAOYSA-N 0.000 description 1
- LQNPLTPLUNBILW-UHFFFAOYSA-N CCOc(cc1OC)nc2c1[s]cc2 Chemical compound CCOc(cc1OC)nc2c1[s]cc2 LQNPLTPLUNBILW-UHFFFAOYSA-N 0.000 description 1
- VBEUTEZVZKUGTD-UHFFFAOYSA-N CCOc(nc12)cc(OC)c1[s]cc2S=O Chemical compound CCOc(nc12)cc(OC)c1[s]cc2S=O VBEUTEZVZKUGTD-UHFFFAOYSA-N 0.000 description 1
- KOEZSCYKERBRCJ-UHFFFAOYSA-N CCOc1cc(OC)c2[s]c(C)c(C)c2n1 Chemical compound CCOc1cc(OC)c2[s]c(C)c(C)c2n1 KOEZSCYKERBRCJ-UHFFFAOYSA-N 0.000 description 1
- LFIUWMBUMYXYLM-UHFFFAOYSA-N CCOc1cc(OC)c2[s]c(C)cc2n1 Chemical compound CCOc1cc(OC)c2[s]c(C)cc2n1 LFIUWMBUMYXYLM-UHFFFAOYSA-N 0.000 description 1
- AZSAQDQHFDUEMX-UHFFFAOYSA-N Cc(c1nc(OCC=C)c2)c[s]c1c2OC Chemical compound Cc(c1nc(OCC=C)c2)c[s]c1c2OC AZSAQDQHFDUEMX-UHFFFAOYSA-N 0.000 description 1
- MTTGGOXMKRBJGP-UHFFFAOYSA-N FC(CC1(CC2)CCCC2NC1)(F)F Chemical compound FC(CC1(CC2)CCCC2NC1)(F)F MTTGGOXMKRBJGP-UHFFFAOYSA-N 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93775207P | 2007-06-29 | 2007-06-29 | |
| US60/937,752 | 2007-06-29 | ||
| US95969807P | 2007-07-16 | 2007-07-16 | |
| US60/959,698 | 2007-07-16 | ||
| PCT/US2008/007928 WO2009005677A2 (en) | 2007-06-29 | 2008-06-26 | Antiviral compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013124380A Division JP2013177452A (ja) | 2007-06-29 | 2013-06-13 | 抗ウイルス化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010532352A JP2010532352A (ja) | 2010-10-07 |
| JP2010532352A5 true JP2010532352A5 (enExample) | 2011-10-27 |
| JP5465667B2 JP5465667B2 (ja) | 2014-04-09 |
Family
ID=40202103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514802A Expired - Fee Related JP5465667B2 (ja) | 2007-06-29 | 2008-06-26 | 抗ウイルス化合物 |
| JP2013124380A Withdrawn JP2013177452A (ja) | 2007-06-29 | 2013-06-13 | 抗ウイルス化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013124380A Withdrawn JP2013177452A (ja) | 2007-06-29 | 2013-06-13 | 抗ウイルス化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8513186B2 (enExample) |
| EP (1) | EP2162432A2 (enExample) |
| JP (2) | JP5465667B2 (enExample) |
| KR (1) | KR20100038417A (enExample) |
| CN (1) | CN101801925A (enExample) |
| AP (1) | AP2009005073A0 (enExample) |
| AR (1) | AR068794A1 (enExample) |
| AU (1) | AU2008271117B2 (enExample) |
| BR (1) | BRPI0813733A2 (enExample) |
| CA (1) | CA2692145C (enExample) |
| CO (1) | CO6251241A2 (enExample) |
| EA (1) | EA200971074A1 (enExample) |
| EC (1) | ECSP109906A (enExample) |
| IL (1) | IL202623A0 (enExample) |
| MX (1) | MX2009013830A (enExample) |
| SG (1) | SG182979A1 (enExample) |
| TW (1) | TW200914013A (enExample) |
| WO (1) | WO2009005677A2 (enExample) |
| ZA (1) | ZA201000614B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| RU2490272C2 (ru) * | 2008-02-04 | 2013-08-20 | Айденикс Фармасьютикалз, Инк. | Макроциклические ингибиторы серинпротеазы |
| US20090285773A1 (en) * | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| CA2737376A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| CA2737958A1 (en) * | 2008-09-23 | 2010-04-01 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| CN102300871A (zh) * | 2008-12-19 | 2011-12-28 | 吉里德科学公司 | Hcv ns3蛋白酶抑制剂 |
| EP2393493A4 (en) * | 2009-01-30 | 2013-07-17 | Glaxosmithkline Llc | LINKS |
| JP2012520891A (ja) * | 2009-03-19 | 2012-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スルホニルキノリンの製造方法 |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| EP2423187A4 (en) | 2009-04-24 | 2015-08-12 | Kaneka Corp | PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS |
| US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
| US20110034469A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Heterocyclic Compound |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| KR20120110090A (ko) * | 2009-09-28 | 2012-10-09 | 에프. 호프만-라 로슈 리미티드 | Ｃ형 간염 바이러스 복제의 신규한 마크로시클릭 저해제 |
| IN2012DN02693A (enExample) * | 2009-09-28 | 2015-09-04 | Intermune Inc | |
| EA201200650A1 (ru) | 2009-10-30 | 2012-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин |
| US20120295845A1 (en) | 2009-11-23 | 2012-11-22 | Pfizer Inc | Imidazo-pyrazoles as gpr119 inhibitors |
| US8476225B2 (en) | 2009-12-04 | 2013-07-02 | Gilead Sciences, Inc. | Antiviral compounds |
| US8815881B2 (en) | 2010-08-09 | 2014-08-26 | Hoffmann-La Roche Inc. | 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds |
| JP5568137B2 (ja) * | 2010-09-22 | 2014-08-06 | 三井化学アグロ株式会社 | 含フッ素カルバマート基を有するアミノ酸アミド誘導体の製造方法、その製造中間体、及びエチレンジアミン誘導体の製造方法 |
| WO2012047764A1 (en) * | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Therapeutic antiviral peptides |
| US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
| EA201390988A1 (ru) | 2010-12-30 | 2014-04-30 | Энанта Фармасьютикалз, Инк. | Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c |
| CA2822556A1 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
| US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| EP2709613B2 (en) | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| US20140100364A1 (en) | 2012-10-08 | 2014-04-10 | Abbvie Inc. | Compounds Useful For Making HCV Protease Inhibitors |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN102937580B (zh) * | 2012-11-02 | 2015-09-02 | 天津科技大学 | 食用油脂中缩水甘油酯的检测方法 |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2642265T3 (es) * | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| EP2950786B1 (en) | 2013-01-31 | 2019-11-27 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| EP3391898A3 (en) * | 2013-03-13 | 2019-02-13 | President and Fellows of Harvard College | Stapled and stitched polypeptides and uses thereof |
| WO2014145095A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Macrocyclic and bicyclic inhibitors of hepatitis c virus |
| JP6449274B2 (ja) | 2013-07-11 | 2019-01-09 | エベストラ インコーポレイテッド | プロドラッグを生成する化合物 |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| CN105504007B (zh) * | 2014-10-14 | 2021-03-16 | 中国药科大学 | 氨基磷酸酯衍生物、其制备方法及其在制药中的用途 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| EA201892375A1 (ru) | 2016-05-27 | 2019-08-30 | Джилид Сайэнс, Инк. | Способы лечения инфекций, вызываемых вирусом гепатита b |
| WO2018026877A1 (en) | 2016-08-05 | 2018-02-08 | Calitor Sciences, Llc | Process for preparing substituted quinolin-4-ol compounds |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| MX2020003470A (es) | 2017-10-19 | 2020-10-01 | Evestra Inc | Anticonceptivos de profarmacos de progestina de accion mas prolongada. |
| PT3706762T (pt) | 2017-12-07 | 2024-12-05 | Univ Emory | N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| KR20210033492A (ko) | 2018-07-16 | 2021-03-26 | 길리애드 사이언시즈, 인코포레이티드 | Hiv의 치료를 위한 캡시드 억제제 |
| CN111056889B (zh) * | 2019-11-22 | 2022-01-11 | 华东师范大学 | 一类n-烷基/n-芳基硫代酰胺衍生物及其合成方法和应用 |
| CA3157275C (en) | 2019-11-26 | 2026-02-10 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| TWI858267B (zh) | 2020-06-25 | 2024-10-11 | 美商基利科學股份有限公司 | 用於治療hiv之蛋白殼抑制劑 |
| KR20230062845A (ko) * | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| CN112961106A (zh) * | 2021-03-13 | 2021-06-15 | 德州学院 | 一种4-羟基-6氯喹啉合成新工艺 |
| CR20240223A (es) | 2021-12-03 | 2024-07-08 | Gilead Sciences Inc | Compuestos terapéuticos para la infección por el virus del vih |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| US12404262B2 (en) | 2021-12-03 | 2025-09-02 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
| US5633388A (en) * | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| WO1997043310A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
| KR100509388B1 (ko) * | 1996-10-18 | 2005-08-23 | 버텍스 파마슈티칼스 인코포레이티드 | 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제 |
| GB9623908D0 (en) * | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| WO1998046597A1 (en) | 1997-04-14 | 1998-10-22 | Emory University | Serine protease inhibitors |
| GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
| ES2234144T3 (es) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | Analogos de peptidos inhibidores de la hepatitis c. |
| WO1999007733A2 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
| IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
| ATE346035T1 (de) | 1998-03-31 | 2006-12-15 | Vertex Pharma | Inhibitoren von serin proteasen, insbesondere von hepatitis c virus ns3 protease |
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| WO2000006529A1 (en) | 1998-07-27 | 2000-02-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Diketoacid-derivatives as inhibitors of polymerases |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| WO2000010573A1 (en) | 1998-08-21 | 2000-03-02 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
| CA2343522A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| KR20010079907A (ko) | 1998-09-25 | 2001-08-22 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병의 치료 및 예방 방법 |
| US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| NZ514403A (en) | 1999-12-27 | 2002-10-25 | Japan Tobacco Inc | Fused-ring compounds and use thereof as drugs |
| WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| DE60119968T2 (de) | 2000-11-20 | 2007-01-18 | Bristol-Myers Squibb Co. | Hepatitis c tripeptid inhibitoren |
| US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
| US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
| CA2369970A1 (en) * | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
| US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| JP4312711B2 (ja) | 2002-05-20 | 2009-08-12 | ブリストル−マイヤーズ スクイブ カンパニー | ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤 |
| WO2004032827A2 (en) * | 2002-05-20 | 2004-04-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| JP4271148B2 (ja) * | 2002-05-20 | 2009-06-03 | ブリストル−マイヤーズ スクイブ カンパニー | 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| CA2515216A1 (en) | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
| CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
| US6908901B2 (en) * | 2003-03-05 | 2005-06-21 | Boehringer Ingelheim International, Gmbh | Hepatitis C inhibitor peptide analogs |
| US7148347B2 (en) * | 2003-04-10 | 2006-12-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
| JP4733023B2 (ja) * | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
| KR101031825B1 (ko) | 2003-04-18 | 2011-04-29 | 이난타 파마슈티칼스, 인코포레이티드 | 거대고리형 퀴녹살리닐 ｃ형 간염 세린 단백질분해효소억제제 |
| CL2004001161A1 (es) | 2003-05-21 | 2005-04-08 | Boehringer Ingelheim Int | Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c. |
| WO2004113365A2 (en) | 2003-06-05 | 2004-12-29 | Enanta Pharmaceuticals, Inc. | Hepatitis c serine protease tri-peptide inhibitors |
| US7125845B2 (en) | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| WO2005037214A2 (en) * | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
| US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ATE495185T1 (de) * | 2004-01-21 | 2011-01-15 | Boehringer Ingelheim Int | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
| AP2006003763A0 (en) * | 2004-03-30 | 2006-10-31 | Intermune Inc | Macrocyclic compounds as inhibitors of viral replication |
| RS51974B (sr) * | 2004-07-16 | 2012-02-29 | Gilead Sciences Inc. | Antivirusna jedinjenja |
| UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
| JP4914355B2 (ja) | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎インヒビターペプチド類似体 |
| WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
| US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
| TW200738742A (en) * | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| US7772183B2 (en) * | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2008
- 2008-06-26 WO PCT/US2008/007928 patent/WO2009005677A2/en not_active Ceased
- 2008-06-26 CN CN200880104330A patent/CN101801925A/zh active Pending
- 2008-06-26 AU AU2008271117A patent/AU2008271117B2/en not_active Ceased
- 2008-06-26 EP EP08779772A patent/EP2162432A2/en not_active Withdrawn
- 2008-06-26 AP AP2009005073A patent/AP2009005073A0/en unknown
- 2008-06-26 JP JP2010514802A patent/JP5465667B2/ja not_active Expired - Fee Related
- 2008-06-26 MX MX2009013830A patent/MX2009013830A/es not_active Application Discontinuation
- 2008-06-26 CA CA2692145A patent/CA2692145C/en not_active Expired - Fee Related
- 2008-06-26 US US12/215,601 patent/US8513186B2/en active Active
- 2008-06-26 AR ARP080102758A patent/AR068794A1/es not_active Application Discontinuation
- 2008-06-26 SG SG2012048484A patent/SG182979A1/en unknown
- 2008-06-26 KR KR1020107002261A patent/KR20100038417A/ko not_active Ceased
- 2008-06-26 EA EA200971074A patent/EA200971074A1/ru unknown
- 2008-06-26 TW TW097123925A patent/TW200914013A/zh unknown
- 2008-06-26 BR BRPI0813733-1A patent/BRPI0813733A2/pt not_active IP Right Cessation
-
2009
- 2009-12-09 IL IL202623A patent/IL202623A0/en unknown
- 2009-12-18 CO CO09145303A patent/CO6251241A2/es not_active Application Discontinuation
-
2010
- 2010-01-27 ZA ZA2010/00614A patent/ZA201000614B/en unknown
- 2010-01-28 EC EC2010009906A patent/ECSP109906A/es unknown
-
2013
- 2013-06-13 JP JP2013124380A patent/JP2013177452A/ja not_active Withdrawn
- 2013-07-01 US US13/932,945 patent/US8809267B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532352A5 (enExample) | ||
| ES2332778T3 (es) | Compuestos de prolina como inhibidores de la proteasa serina ns3 para uso en el tratamiento de infeccion por el virus de la hepatitis c. | |
| JP4682155B2 (ja) | Ｃ型肝炎ウイルスに対して活性な大環状ペプチド | |
| ES2327544T3 (es) | Compuestos novedosos como inhibidores de serina proteasa ns3 de virus de hepetitis c. | |
| US6323180B1 (en) | Hepatitis C inhibitor tri-peptides | |
| JP4688815B2 (ja) | Ｃ型肝炎ウイルスインヒビター | |
| EP1771453B1 (en) | Hepatitis c inhibitor dipeptide analogs | |
| JP4398424B2 (ja) | Ｃ型肝炎ウィルスに対する活性を有する大環状ペプチド | |
| CN101228169B (zh) | 丙型肝炎病毒的大环抑制剂 | |
| JP2012504632A5 (enExample) | ||
| US20040077551A1 (en) | Substituted cycloalkyl P1' hepatitis C virus inhibitors | |
| ZA200100972B (en) | Hepatituis C inhibitor peptides. | |
| CA2683639A1 (en) | Sulfur compounds as inhiibitors of hepatitis c virus ns3 serine protease | |
| WO2005007681A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| JP2010508361A5 (enExample) | ||
| EP1506000A1 (en) | Heterocyclicsulfonamide hepatitis c virus inhibitors | |
| CA2536570A1 (en) | Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus | |
| EP1684745A2 (en) | Hepatitis c virus inhibitors | |
| ATE349463T1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| DE602004023924D1 (en) | Ease-hemmer | |
| JP2014534206A (ja) | Ｃ型肝炎ウイルス阻害剤 | |
| JP2011517673A5 (enExample) |